Celyad Appoints Filippo Petti as Chief Financial Officer

Celyad Appoints Filippo Petti as Chief Financial Officer

Dr. Margo Roberts joins Celyad’s Board of Directors and Scientific Committee

Dr. Margo Roberts joins Celyad’s Board of Directors and Scientific Committee

Celyad Announces FDA Acceptance of IND Application for CYAD-101, a First-in-Class Non-Gene Edited Allogeneic CAR-T Candidate

Celyad Announces FDA Acceptance of IND Application for CYAD-101, a First-in-Class Non-Gene Edited Allogeneic CAR-T Candidate

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy

Celyad doses first AML patient at final dose level in CYAD-01 THINK trial and treats first patient with second cycle of therapy

Celyad announces closing of global offering

Celyad announces closing of global offering

Expression of a TIM peptide reduces alloreactivity of T-cells facilitating an allogeneic NKG2D Chimeric Antigen Receptor T-cell therapy approach

Expression of a TIM peptide reduces alloreactivity of T-cells facilitating an allogeneic NKG2D Chimeric Antigen Receptor T-cell therapy approach

Celyad announces pricing of $47.3 million global offering

Celyad announces pricing of $47.3 million global offering

Functional screening of an anti-B7H6 specific chimeric antigen receptor (CAR)

Functional screening of an anti-B7H6 specific chimeric antigen receptor (CAR)

Overcoming target-driven fratricide for CAR-T cell therapy

Overcoming target-driven fratricide for CAR-T cell therapy

Celyad announces launch of proposed global offering

Celyad announces launch of proposed global offering

Celyad Announces First Quarter 2018 Business Update

Celyad Announces First Quarter 2018 Business Update

Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018

Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018